Bagualing Community Health Service Centre, The Eighth Affiliated Hospital, SUN YAT-SEN University, 518033 Shenzhen, Guangdong, China.
Department of Rehabilitation Medicine, The Eighth Affiliated Hospital, SUN YAT-SEN University, 518033 Shenzhen, Guangdong, China.
J Integr Neurosci. 2021 Jun 30;20(2):349-357. doi: 10.31083/j.jin2002034.
As there is no clear biomarker to diagnose Parkinson's disease, this meta-analysis aims to comprehensively evaluates the correlation between serum Cystatin C levels and Parkinson's disease in the Chinese population by the meta-analysis method. PubMed, Web of Science, Embase, Cochrane Library, China national knowledge infrastructure, and China WanFang databases were systematically searched on the correlation between serum Cystatin C and Parkinson's disease. The results showed that Cystatin C level in Parkinson's disease patients compared with the control group, the standardized mean difference = 1.78 (95% CI: 1.332.24, < 0.05). The level of Cystatin C in the late Parkinson's disease stage compared with that in the mid-term of Parkinson's disease, the standardized mean difference was = 0.78 (95% CI: 0.081.49, < 0.05). The Cystatin C level in the mid-term of Parkinson's disease compared with that in the early Parkinson's disease stage, the standardized mean difference was 1.24 (95% CI: 0.352.12, < 0.05). The level of Cystatin C in Parkinson's disease with mild cognitive impairment compared with Parkinson's disease without mild cognitive impairment, the standardized mean difference was 1.29 (95% CI: 0.472.10, < 0.05). The differences were all statistically significant. In conclusion, a high level of serum Cystatin C may be involved in the occurrence and development of Parkinson's disease, whose level is higher in Parkinson's disease patients with mild cognitive impairment than that in Parkinson's disease without mild cognitive impairment. Therefore, Cystatin C in serum is a promising biomarker for diagnosing Parkinson's disease.
由于目前尚无明确的生物标志物可用于诊断帕金森病，本研究旨在通过荟萃分析方法，综合评估血清胱抑素 C 水平与中国人群帕金森病之间的相关性。系统检索了PubMed、Web of Science、Embase、Cochrane Library、中国知网和万方数据库中关于血清胱抑素 C 与帕金森病相关性的研究。结果表明，与对照组相比，帕金森病患者的血清胱抑素 C 水平标准化均数差=1.78（95%CI：1.332.24， < 0.05）。与中期帕金森病相比，晚期帕金森病患者的血清胱抑素 C 水平标准化均数差=0.78（95%CI：0.081.49， < 0.05）。与早期帕金森病相比，中期帕金森病患者的血清胱抑素 C 水平标准化均数差=1.24（95%CI：0.352.12， < 0.05）。与无轻度认知障碍的帕金森病患者相比，有轻度认知障碍的帕金森病患者的血清胱抑素 C 水平标准化均数差=1.29（95%CI：0.472.10， < 0.05）。这些差异均具有统计学意义。总之，高水平的血清胱抑素 C 可能参与了帕金森病的发生和发展，且伴有轻度认知障碍的帕金森病患者的血清胱抑素 C 水平高于无轻度认知障碍的帕金森病患者。因此，血清胱抑素 C 可能是一种有前景的帕金森病诊断生物标志物。
